Business
Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies
New strategy aligns with ongoing shift in oncology standard-of-caretowards combination therapies Combination therapy focus expected to improve the Company’s
About this update from Allarity Therapeutics, Inc.
[{"type":"text","content":"New strategy aligns with ongoing shift in oncology standard-of-caretowards combination therapies Combination therapy focus expected to improve the Company’s future funding and commercial prospects New pipeline strategy follows Type C meeting held with FDA regarding dovitinib clinical development path for third-line mRCC Press release Cambridge, MA, U.S.A. (August 2, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced that its Board of Directors has mandated a refocus of the Company’s oncology pipeline strategy away from development of monotherapies towards development of more promising and clinically relevant combination therapies. Following a lengthy and in-depth analysis of current pipeline opportunities, clinical/commercial/ regulatory risks, development costs and timelines, expected availability of funding, and in consultation with Allarity’s senior management, its Scientific Advisory Board (SAB), and external experts, Allarity’s Board of Directors has concluded that refocusing the Company’s pipeline to development of combination therapies will accomplish the following: Align with the ongoing shift in cancer therapy standard-of-care away from monotherapies toward combination therapies, which are increasingly driving market opportunities and which have shown dramatic increases in patient benefit.Strengthen the Company’s ability to attract additional funding from institutional life science investors, which is necessary to support the Company’s clinical development activities and future success.Significantly broaden the Company’s possibilities for future commercial partnering with larger pharmaceutical companies to maximize the value of its pipeline assets and DRP® platform technology.Improve the likelihood of clinical and commercial success of the Company’s pipeline assets. The Board’s decision also takes into account feedback that the Company recently received from the U.S. Food and Drug Administration (FDA) from a Type C advisory meeting held in Q2 2022, regarding a potential Phase 3 clinical development path for dovitinib as a monotherapy third-line treatment for metastatic renal cell carcinoma (mRCC). As part of that feedback, the ...